Brief: Curevac Q4 Pre-Tax Loss At EUR 38.6 Mln

CureVac NV

10/04/2025 12:20

April 10 (Reuters) - CUREVAC NV 5CV.DE:

ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2024 AND PROVIDES BUSINESS UPDATE

COMPLETED ENROLLMENT OF PART B PHASE 1 GLIOBLASTOMA STUDY

CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 481.7 MILLION AT END OF DECEMBER 2024, INCREASING FROM EUR 402.5 MILLION AT END OF 2023

REVENUES AMOUNTED TO EUR 14.5 MILLION AND EUR 535.2 MILLION FOR THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2024, RESPECTIVELY, REPRESENTING A DECREASE OF EUR 8.1 MILLION AND AN INCREASE OF EUR 481.4 MILLION FROM EUR 22.6 MILLION AND EUR 53.8 MILLION FOR SAME PERIODS IN 2023.

IN 2024, CASH USED IN OPERATIONS WAS MAINLY ALLOCATED TO EXTRAORDINARY PAYMENTS AMOUNTING TO A TOTAL OF EUR 137 MILLION

COMPANY REAFFIRMS ITS EXPECTED CASH RUNWAY INTO 2028

OPERATING LOSS AMOUNTED TO EUR 43.8 MILLION FOR THREE MONTHS ENDED DECEMBER 31, 2024

REVENUE INCREASE YEAR-ON-YEAR WAS PRIMARILY DRIVEN BY NEW LICENSE AGREEMENT WITH GSK, WHICH CLOSED IN JULY 2024

JURY TRIAL IN U.S. LITIGATION POSTPONED TO SEPTEMBER 8, 2025

OPERATING PROFIT AMOUNTED TO EUR 177.7 MILLION FOR TWELVE MONTHS ENDED DECEMBER 31, 2024

PRE-TAX LOSS WAS EUR 38.6 MILLION FOR THREE MONTHS ENDED DECEMBER 31, 2024

PRE-TAX PROFIT WAS EUR 190.9 MILLION FOR TWELVE MONTHS ENDED DECEMBER 31, 2024

PART B OF GLIOSBLASTOMA STUDY FIRST DATA READOUT ANTICIPATED IN H2 2025

Source text: ID:nEQ200zWYa

Further company coverage: 5CV.DE

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))